{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,20]],"date-time":"2026-03-20T22:53:08Z","timestamp":1774047188237,"version":"3.50.1"},"reference-count":68,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T00:00:00Z","timestamp":1737072000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100001871","name":"Funda\u00e7\u00e3o para a Ci\u00eancia e a Tecnologia","doi-asserted-by":"publisher","award":["UID\/DTP\/04138\/2021"],"award-info":[{"award-number":["UID\/DTP\/04138\/2021"]}],"id":[{"id":"10.13039\/501100001871","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Stem Cell Rev and Rep"],"published-print":{"date-parts":[[2025,4]]},"DOI":"10.1007\/s12015-024-10838-9","type":"journal-article","created":{"date-parts":[[2025,1,17]],"date-time":"2025-01-17T08:00:28Z","timestamp":1737100828000},"page":"645-679","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":15,"title":["Quality and Regulatory Requirements for the Manufacture of Master Cell Banks of Clinical Grade iPSCs: The EU and USA Perspectives"],"prefix":"10.1007","volume":"21","author":[{"given":"Fernando","family":"Martins","sequence":"first","affiliation":[]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5693-7861","authenticated-orcid":false,"given":"Maria H. L.","family":"Ribeiro","sequence":"additional","affiliation":[]}],"member":"297","published-online":{"date-parts":[[2025,1,17]]},"reference":[{"key":"10838_CR1","unstructured":"Stem Cells: From embryonic origin to induced pluripotency \u2013 an overview. (2021). Stem cells from embryonic origin to induced pluripotency an overview - Enzo life sciences. https:\/\/www.enzolifesciences.com\/science-center\/technotes\/2019\/august\/stem-cells-from-embryonic-origin-to-induced-pluripotency-an-overview\/"},{"key":"10838_CR2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2021\/9978837","volume":"2021","author":"IA Charitos","year":"2021","unstructured":"Charitos, I. A., Ballini, A., Cantore, S., Boccellino, M., Di Domenico, M., Borsani, E., et al. (2021). Stem cells: A historical review about biological, religious, and ethical issues. Mascitti M, editor. Stem Cells International, 2021, 1\u201311.","journal-title":"Stem Cells International"},{"key":"10838_CR3","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1155\/2016\/9451492","volume":"2016","author":"A Romito","year":"2016","unstructured":"Romito, A., & Cobellis, G. (2016). Pluripotent stem cells: Current understanding and future directions. Stem Cells International, 2016, 1\u201320.","journal-title":"Stem Cells International"},{"issue":"20","key":"10838_CR4","doi-asserted-by":"crossref","first-page":"2239","DOI":"10.1101\/gad.1963910","volume":"24","author":"M Stadtfeld","year":"2010","unstructured":"Stadtfeld, M., & Hochedlinger, K. (2010). Induced pluripotency: History, mechanisms, and applications. Genes & Development, 24(20), 2239\u201363.","journal-title":"Genes & Development"},{"issue":"12","key":"10838_CR5","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1631\/jzus.B1300215","volume":"14","author":"J Zhao","year":"2013","unstructured":"Zhao, J., Jiang, W., Sun, C., Hou, C., Yang, X., & Gao, J. (2013). Induced pluripotent stem cells: Origins, applications, and future perspectives. Journal of Zhejiang University Science B, 14(12), 1059\u20131069.","journal-title":"Journal of Zhejiang University Science B"},{"key":"10838_CR6","doi-asserted-by":"crossref","first-page":"e4370","DOI":"10.7717\/peerj.4370","volume":"6","author":"AE Omole","year":"2018","unstructured":"Omole, A. E., & Fakoya, A. O. J. (2018). Ten years of progress and promise of induced pluripotent stem cells: Historical origins, characteristics, mechanisms, limitations, and potential applications. PeerJ, 6, e4370.","journal-title":"PeerJ"},{"issue":"1","key":"10838_CR7","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1007\/s12015-019-09935-x","volume":"16","author":"G Liu","year":"2020","unstructured":"Liu, G., David, B. T., Trawczynski, M., & Fessler, R. G. (2020). Advances in pluripotent stem cells: History, mechanisms, technologies, and applications. Stem Cell Reviews and Reports, 16(1), 3\u201332.","journal-title":"Stem Cell Reviews and Reports"},{"issue":"1","key":"10838_CR8","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/embor.2012.197","volume":"14","author":"E Fuchs","year":"2013","unstructured":"Fuchs, E., & Chen, T. (2013). A matter of life and death: Self-renewal in stem cells. EMBO Reports, 14(1), 39\u201348.","journal-title":"EMBO Reports"},{"issue":"9","key":"10838_CR9","doi-asserted-by":"crossref","first-page":"1060","DOI":"10.1038\/s41556-019-0384-4","volume":"21","author":"L Liu","year":"2019","unstructured":"Liu, L., Michowski, W., Kolodziejczyk, A., & Sicinski, P. (2019). The cell cycle in stem cell proliferation, pluripotency and differentiation. Nature Cell Biology, 21(9), 1060\u20131067.","journal-title":"Nature Cell Biology"},{"issue":"10","key":"10838_CR10","doi-asserted-by":"crossref","first-page":"1548","DOI":"10.3390\/genes12101548","volume":"12","author":"AI Chen","year":"2021","unstructured":"Chen, A. I., Peng, Q., Fong, S., Lee, K. F., Yeung, W. S. B., & Lee, Y. L. (2021). DNA damage response and cell cycle regulation in pluripotent stem cells. Genes, 12(10), 1548\u20138.","journal-title":"Genes"},{"key":"10838_CR11","doi-asserted-by":"publisher","unstructured":"Siddiqui, S. (2015). Therapeutic potential of totipotent, pluripotent and multipotent stem cells. MOJ Cell Science & Report, 2(5), 136\u2013141. https:\/\/doi.org\/10.15406\/mojcsr.2015.02.00041","DOI":"10.15406\/mojcsr.2015.02.00041"},{"key":"10838_CR12","doi-asserted-by":"publisher","unstructured":"El-Kadiry, A. E. H., Rafei, M., & Shammaa, R. (2021). Cell therapy: Types, regulation, and clinical benefits. Frontiers in Medicine,\u00a08, 756029. https:\/\/doi.org\/10.3389\/fmed.2021.756029","DOI":"10.3389\/fmed.2021.756029"},{"key":"10838_CR13","doi-asserted-by":"publisher","unstructured":"Zakrzewski, W., Dobrzy\u0144ski, M., Szymonowicz, M., & Rybak, Z. (2019). Stem cells: Past, present, and future. Stem Cell Research & Therapy, 10(1), 68.\u00a0https:\/\/doi.org\/10.1186\/s13287-019-1165-5","DOI":"10.1186\/s13287-019-1165-5"},{"key":"10838_CR14","unstructured":"What are Progenitor Cells? Exploring neural, myeloid and hematopoietic progenitor cells. Cell science from technology networks. https:\/\/www.technologynetworks.com\/cell-science\/articles\/what-are-progenitor-cells-exploring-neural-myeloid-and-hematopoietic-progenitor-cells-329519#:~:text=While%20some%20progenitor%20cells%20are"},{"key":"10838_CR15","doi-asserted-by":"crossref","first-page":"662360","DOI":"10.3389\/fimmu.2021.662360","volume":"12","author":"C Flahou","year":"2021","unstructured":"Flahou, C., Morishima, T., Takizawa, H., & Sugimoto, N. (2021). Fit-for-all iPSC-derived cell therapies and their evaluation in humanized mice with NK cell immunity. Frontiers in Immunology, 12, 662360.","journal-title":"Frontiers in Immunology"},{"issue":"2","key":"10838_CR16","doi-asserted-by":"crossref","first-page":"18","DOI":"10.32607\/20758251-2010-2-2-18-27","volume":"2","author":"SP Medvedev","year":"2010","unstructured":"Medvedev, S. P., Shevchenko, A. I., & Zakian, S. M. (2010). Induced pluripotent stem cells: Problems and advantages when applying them in regenerative medicine. Acta Naturae, 2(2), 18\u201327.","journal-title":"Acta Naturae"},{"issue":"3","key":"10838_CR17","doi-asserted-by":"crossref","first-page":"204","DOI":"10.1210\/er.2008-0031","volume":"30","author":"B Lo","year":"2009","unstructured":"Lo, B., & Parham, L. (2009). Ethical issues in stem cell research. Endocrine Reviews, 30(3), 204\u201313.","journal-title":"Endocrine Reviews"},{"issue":"2","key":"10838_CR18","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1089\/cell.2013.0072","volume":"16","author":"V Pican\u00e7o-Castro","year":"2014","unstructured":"Pican\u00e7o-Castro, V., Moreira, L. F., Kashima, S., & Covas, D. T. (2014). Can pluripotent stem cells used in cell-based therapy? Cellular Reprogramming, 16(2), 98\u2013107.","journal-title":"Cellular Reprogramming"},{"issue":"4","key":"10838_CR19","doi-asserted-by":"crossref","first-page":"647","DOI":"10.1016\/j.stemcr.2015.08.015","volume":"5","author":"B Baghbaderani","year":"2015","unstructured":"Baghbaderani, B., Tian, X., Neo, B., Burkall, A., Dimezzo, T., Sierra, G., et al. (2015). cGMP-manufactured human induced pluripotent stem cells are available for pre-clinical and clinical applications. Stem Cell Reports, 5(4), 647\u201359.","journal-title":"Stem Cell Reports"},{"issue":"1","key":"10838_CR20","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1186\/s13287-020-01987-y","volume":"11","author":"S Ballikaya","year":"2020","unstructured":"Ballikaya, S., Sadeghi, S., Niebergall-Roth, E., Nimtz, L., Frindert, J., Norrick, A., Stemler, N., Bauer, N., Rosche, Y., Kratzenberg, V., Pieper, J., Ficek, T., Frank, M. H., Ganss, C., Esterlechner, J., & Kluth, M. A. (2020). Process data of allogeneic ex vivo-expanded ABCB5+ mesenchymal stromal cells for human use: off-the-shelf GMP-manufactured donor-independent ATMP. Stem Cell Research & Therapy, 11(1), 482.","journal-title":"Stem Cell Research & Therapy"},{"key":"10838_CR21","unstructured":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use ICH harmonised tripartite guideline derivation and characterisation of cell substrates used for production of biotechnological\/biological products Q5D. (1997). https:\/\/database.ich.org\/sites\/default\/files\/Q5D%20Guideline.pdf"},{"key":"10838_CR22","unstructured":"USP 36 - NF 31 The United States Pharmacopeia and National Formulary. (2013). Cellular and tissue-based products.\u00a0https:\/\/www.uspnf.com\/official-text\/proposal-statuscommentary\/usp-36-nf-31"},{"key":"10838_CR23","unstructured":"Committee for Medicinal Product for Human Use (CHMP). (2006). Guideline on human cell-based medicinal products draft agreed by CPWP and BWP adoption by CHMP for release for consultation. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-human-cell-based-medicinal-products_en.pdf"},{"issue":"10","key":"10838_CR24","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1089\/hum.1998.9.10-1513","volume":"9","author":"FDA Report","year":"1998","unstructured":"Report, F. D. A. (1998). Guidance for industry: Guidance for human somatic cell therapy and gene therapy. Human Gene Therapy, 9(10), 1513\u20131524.","journal-title":"Human Gene Therapy"},{"key":"10838_CR25","unstructured":"U S Food and Drug Administration. (2021). Points to consider in the characterization of cell lines used to produce biologicals. U.S. Food and Drug Administration. Fda.gov. https:\/\/www.fda.gov\/"},{"key":"10838_CR26","unstructured":"Annex 3 Recommendations for the evaluation of animal cell cultures as substrates for the manufacture of biological medicinal products and for the characterization of cell banks Replacement of Annex 1 of WHO Technical Report Series, No. 878. https:\/\/cdn.who.int\/media\/docs\/default-source\/biologicals\/documents\/trs_978_annex_3.pdf?sfvrsn=fe61af77_3&download=true"},{"key":"10838_CR27","doi-asserted-by":"crossref","unstructured":"(2006). Guidance for industry: Characterization and qualification of cell substrates and other biological starting materials used in the production of viral vaccines for the prevention and treatment of infectious diseases. Biotechnology Law Report, 25(6), 697\u2013723. https:\/\/www.fda.gov\/media\/78428\/download","DOI":"10.1089\/blr.2006.25.697"},{"issue":"1","key":"10838_CR28","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jcyt.2022.08.001","volume":"25","author":"JL Dashnau","year":"2023","unstructured":"Dashnau, J. L., Xue, Q., Nelson, M., Law, E., Cao, L., & Hei, D. (2023). A risk-based approach for cell line development, manufacturing and characterization of genetically engineered, induced pluripotent stem cell\u2013derived allogeneic cell therapies. Cytotherapy, 25(1), 1\u201313.","journal-title":"Cytotherapy"},{"key":"10838_CR29","unstructured":"Directive 2004\/23\/EC - European tissues and cells directive. https:\/\/eur-lex.europa.eu\/LexUriServ\/LexUriServ.do?uri=OJ:L:2004:102:0048:0058:en:PDF"},{"key":"10838_CR30","unstructured":"Commission Directive 2006\/17\/EC regarding certain technical requirements for the donation, procurement and testing of human tissues and cells. https:\/\/eur-lex.europa.eu\/LexUriServ\/LexUriServ.do?uri=OJ:L:2006:038:0040:0052:EN:PDF"},{"key":"10838_CR31","unstructured":"Guidance to industry eligibility determination for donors of human cells, tissues, and cellular and tissue-based products (HCT\/Ps). https:\/\/www.fda.gov\/files\/vaccines,%20blood%20&%20biologics\/published\/Eligibility-Determination-for-Donors-of-Human-Cells--Tissues--and-Cellular-and-Tissue-Based-Products--Guidance-for-Industry.pdf"},{"key":"10838_CR32","unstructured":"Euro GTP Guidance European Union Project in the framework of the public health program agreement number: 2007 207 coordinator: Transplant services foundation. http:\/\/goodtissuepractices.eu\/images\/outcomes\/EuroGTP_Final_Delivery.pdf"},{"key":"10838_CR33","unstructured":"Council of Europe, European pharmacopoeia commission, European directorate for the quality of medicines & healthcare. European pharmacopoeia. Strasbourg: Council of Europe; 2019. Ph. Eur. 5.2.12 general chapter on raw materials of biological origin for the production of cell based and gene therapy medicinal products. https:\/\/www.ema.europa.eu\/en\/human-regulatory-overview\/advanced-therapy-medicinal-products-overview\/guidelines-relevant-advanced-therapy-medicinal-products"},{"key":"10838_CR34","unstructured":"Council of Europe, European pharmacopoeia commission, European directorate for the quality of medicines & healthcare. European pharmacopoeia. Strasbourg: Council of Europe; 2019. Ph. Eur. 5.1.7. Viral Safety. http:\/\/www.uspbpep.com\/ep60\/5.1.%207.%20viral%20safety%2050107e.pdf"},{"key":"10838_CR35","unstructured":"The European agency for the evaluation of medicinal products evaluation of medicines for human use. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/note-guidance-plasma-derived-medicinal-products_en.pdf"},{"key":"10838_CR36","unstructured":"Center for Biologics Evaluation and Research. (2019). Characterization and qualification of cell substrates and other biological materials used in the production of viral vaccines for infectious disease indications. U.S. Food and Drug Administration. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/characterization-and-qualification-cell-substrates-and-other-biological-materials-used-production"},{"key":"10838_CR37","unstructured":"Points to consider in the collection, processing, and testing of ex-vivo-activated mononuclear leukocytes for administration to humans. https:\/\/www.fda.gov\/files\/vaccines%2C%20blood%20%26%20biologics\/published\/Points-to-Consider-in-the-Collection--Processing--and-Testing-of-Ex-Vivo-Activated-Mononuclear-Leukocytes-for-Administration-to-Humans.pdf"},{"key":"10838_CR38","unstructured":"EudraLex - Volume 4 Guidelines GMP for ATMPS. health.ec.europa.eu. https:\/\/health.ec.europa.eu\/medicinal-products\/eudralex\/eudralex-volume-4_en"},{"key":"10838_CR39","unstructured":"Federal Register: Request Access. unblock.federalregister.gov. [cited 2023 Oct 29]. https:\/\/www.ecfr.gov\/current\/title-21\/chapter-I\/subchapter-L\/part-1271\/subpart-D?toc=1"},{"issue":"8","key":"10838_CR40","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1016\/j.jcyt.2021.03.007","volume":"23","author":"OA Krasilnikova","year":"2021","unstructured":"Krasilnikova, O. A., Klabukov, I. D., Baranovskii, D. S., Shegay, P. V., & Kaprin, A. D. (2021). The new legal framework for minimally manipulated cells expands the possibilities for cell therapy in Russia. Cytotherapy, 23(8), 754\u2013755.","journal-title":"Cytotherapy"},{"key":"10838_CR41","unstructured":"Committee for Medicinal Products for Human Use (CHMP) Guideline on potency testing of cell based immunotherapy medicinal products for the treatment of cancer. (2016). https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-potency-testing-cell-based-immunotherapy-medicinal-products-treatment-cancer-revision-1_en.pdf"},{"key":"10838_CR42","unstructured":"Reflection paper on management of clinical risks deriving from insertional mutagenesis Reflection paper on management of clinical risks deriving from insertional mutagenesis. (2013). https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-management-clinical-risks-deriving-insertional-mutagenesis_en.pdf"},{"key":"10838_CR43","unstructured":"Council of Europe, European pharmacopoeia commission, European directorate for the quality of medicines & healthcare. European pharmacopoeia. Strasbourg: Council of Europe; 2019. Ph. Eur 5.14. Gene transfer medicinal products.\u00a0https:\/\/www.drugfuture.com\/Pharmacopoeia\/EP7\/DATA\/51400E.PDF"},{"key":"10838_CR44","unstructured":"Official address Domenico Scarlattilaan 6 \u2022 1083 HS Amsterdam \u2022 The Netherlands. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-quality-non-clinical-clinical-aspects-medicinal-products-containing-genetically-modified_en-0.pdf"},{"key":"10838_CR45","unstructured":"ICH topic Q 5 B quality of biotechnological products: Analysis of the expression construct in cell lines used for production of r-DNA derived protein products step 5 note for guidance on quality of biotechnolo-gical products: Analysis of the expression construct in cell lines used for production of r-DNA derived protein products quality of biotechnological products: Analysis of the expression construct in cells used for production of r-DNA derived protein products ICH harmonised tripartite guideline. (1996). https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-q-5-b-analysis-expression-construct-cell-lines-used-production-r-dna-derived-protein-products_en.pdf"},{"key":"10838_CR46","unstructured":"Center for Biologics Evaluation and Research. (2022). Human gene therapy products incorporating human genome editing. U.S. Food and Drug Administration. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/human-gene-therapy-products-incorporating-human-genome-editing"},{"key":"10838_CR47","unstructured":"Center for Biologics Evaluation and Research. (2020). Chemistry, manufacturing, and control (CMC) information for human gene therapy investigational new drug applications (INDs). U.S. Food and Drug Administration. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/chemistry-manufacturing-and-control-cmc-information-human-gene-therapy-investigational-new-drug"},{"key":"10838_CR48","unstructured":"Center for Biologics Evaluation and Research. (2019). Recommendations for microbial vectors used for gene therapy. U.S. Food and Drug Administration. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/recommendations-microbial-vectors-used-gene-therapy"},{"key":"10838_CR49","unstructured":"Center for Biologics Evaluation and Research. (2020). Testing of retroviral vector-based human gene therapy products for replication competent retrovirus during product manufacture and patient follow-up. www.fda.gov. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/testing-retroviral-vector-based-human-gene-therapy-products-replication-competent-retrovirus-during"},{"key":"10838_CR50","unstructured":"7 Westferry Circus \u2022 Canary Wharf \u2022 London E14 4HB \u2022 United Kingdom Reflection paper on stem cell-based medicinal products Reflection paper on stem cell-based medicinal products. (2010). https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/reflection-paper-stem-cell-based-medicinal-products_en.pdf"},{"key":"10838_CR51","unstructured":"Council Of Europe, European Pharmacopoeia Commission, European Directorate For The Quality Of Medicines & Healthcare. European pharmacopoeia. Strasbourg: Council Of Europe; 2019. Ph. Eur. Monograph 2.7.23. Numeration of CD34\/CD45+ cells in haematopoietic products. https:\/\/www.drugfuture.com\/Pharmacopoeia\/EP7\/DATA\/20723E.PDF"},{"key":"10838_CR52","unstructured":"Center for Biologics Evaluation and Research. (2022). Considerations for the development of chimeric antigen receptor (CAR) T cell products. U.S. Food and Drug Administration. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/considerations-development-chimeric-antigen-receptor-car-t-cell-products"},{"key":"10838_CR53","unstructured":"ICH Topic Q 5 C Quality of biotechnological products: Stability testing of biotechnological\/biological products step 5 note for guidance on quality of biotechnolo-gical products: Stability testing of biotechnological\/biological products final approval by CPMP December 1995 proposed date for coming into operation. (1996). https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-topic-q-5-c-quality-biotechnological-products-stability-testing-biotechnological\/biological-products_en.pdf"},{"key":"10838_CR54","unstructured":"ICH Topic Q 5 A (R1) Quality of biotechnological products: Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin step 5 note for guidance on quality of biotechnological products: Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. (1997). https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-q-5-r1-viral-safety-evaluation-biotechnology-products-derived-cell-lines-human-animal-origin_en.pdf"},{"key":"10838_CR55","unstructured":"Council of Europe, European Pharmacopoeia Commission, European Directorate for the quality of medicines & healthcare. European pharmacopoeia. Strasbourg: Council of Europe; 2019. Ph. Eur. 5.2.3. Cell substrates for the production of vaccines for human use. https:\/\/www.edqm.eu\/documents\/52006\/66555\/03-vaccines-immunosera-human-use.pdf\/1f1a0380-6e92-e068-e0c7-223bf80a25a4?t=1623145902950"},{"key":"10838_CR56","unstructured":"USP 36 - NF 31 The United States pharmacopeia and national formulary. (2013). Viral safety evaluation of biotechnology products derived from cell lines of human or animal origin. https:\/\/www.uspnf.com\/official-text\/proposal-statuscommentary\/usp-36-nf-31"},{"key":"10838_CR57","unstructured":"ICH Topic Q 6 B Specifications: Test procedures and acceptance criteria for biotechnological\/biological products step 5 note for guidance on specifications: Test procedures and acceptance criteria for biotechnological\/biological products. (1999). https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/ich-q-6-b-test-procedures-acceptance-criteria-biotechnological\/biological-products-step-5_en.pdf"},{"key":"10838_CR58","unstructured":"European Medicines Agency (EMA). (2019). Guideline on quality, non-clinical and clinical requirements for investigational advanced therapy medicinal products in trials - Scientific guideline. https:\/\/www.ema.europa.eu\/en\/guideline-quality-non-clinical-clinical-requirements-investigational-advanced-therapy-medicinal#current-version--section"},{"key":"10838_CR59","unstructured":"Center for Biologics Evaluation and Research. (2019). Potency tests for cellular and gene therapy products. U.S. Food and Drug Administration. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/potency-tests-cellular-and-gene-therapy-products"},{"key":"10838_CR60","unstructured":"Committee for Medicinal Products for Human Use (CHMP). (2022). Guideline on the requirements for quality documentation concerning biological investigational medicinal products in clinical trials Adoption by CHMP for release for consultation End of consultation (deadline for comments) 31. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-requirements-quality-documentation-concerning-biological-investigational-medicinal_en-2.pdf"},{"key":"10838_CR61","unstructured":"CHMP\/BWP (Committee Abbreviation). (2006). Guideline on virus safety evaluation of biotechnological investigational medicinal products draft agreed by BWP adoption by chmpfor release for consultation guideline on virus safety evaluation of biotechnological investigational medicinal products. https:\/\/www.ema.europa.eu\/en\/documents\/scientific-guideline\/guideline-virus-safety-evaluation-biotechnological-investigational-medicinal-products_en.pdf"},{"key":"10838_CR62","unstructured":"Center for Drug Evaluation and Research. (2020). Current Good Manufacturing Practice for Phase 1 Investigational Drugs. U.S. Food and Drug Administration. https:\/\/www.fda.gov\/regulatory-information\/search-fda-guidance-documents\/current-good-manufacturing-practice-phase-1-investigational-drugs"},{"issue":"7","key":"10838_CR63","doi-asserted-by":"crossref","first-page":"2435","DOI":"10.3390\/ijms21072435","volume":"21","author":"D Rehakova","year":"2020","unstructured":"Rehakova, D., Souralova, T., & Koutna, I. (2020). Clinical-grade human pluripotent stem cells for cell therapy: Characterization strategy. International Journal of Molecular Sciences, 21(7), 2435.","journal-title":"International Journal of Molecular Sciences"},{"issue":"6","key":"10838_CR64","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1007\/s40259-021-00503-9","volume":"35","author":"A Rivera-Ordaz","year":"2021","unstructured":"Rivera-Ordaz, A., Peli, V., Manzini, P., Barilani, M., & Lazzari, L. (2021). Critical analysis of cGMP large-scale expansion process in bioreactors of human induced pluripotent stem cells in the framework of quality by design. BioDrugs, 35(6), 693\u2013714.","journal-title":"BioDrugs"},{"issue":"S2","key":"10838_CR65","doi-asserted-by":"crossref","first-page":"S85","DOI":"10.1002\/sct3.13035","volume":"10","author":"J Cao","year":"2021","unstructured":"Cao, J., Hao, J., Wang, L., Tan, Y., Tian, Y., Li, S., et al. (2021). Developing standards to support the clinical translation of stem cells. Stem Cells Translational Medicine, 10(S2), S85-95.","journal-title":"Stem Cells Translational Medicine"},{"issue":"12","key":"10838_CR66","doi-asserted-by":"crossref","first-page":"3232","DOI":"10.3390\/biomedicines10123232","volume":"10","author":"JJ Lee","year":"2022","unstructured":"Lee, J. J., Lin, C. Y., Chen, H. C., Hsieh, P. C. H., Chiu, Y. W., & Chang, J. M. (2022). Opportunities and challenges of human IPSC technology in kidney disease research. Biomedicines, 10(12), 3232.","journal-title":"Biomedicines"},{"key":"10838_CR67","doi-asserted-by":"publisher","unstructured":"Babu, S. S., Duvvuru, H., Baker, J., Switalski, S., Shafa, M., Panchalingam, K. M., et al. (2023). Characterization of human induced pluripotent stems cells: Current approaches, challenges, and future solutions. Biotechnology Reports, e00784. https:\/\/doi.org\/10.1016\/j.btre.2023.e00784","DOI":"10.1016\/j.btre.2023.e00784"},{"key":"10838_CR68","doi-asserted-by":"crossref","unstructured":"Huang, C. Y., Liu, C. L., Ting, C. Y., Chiu, Y. T., Cheng, Y. C, Nicholson, M. W., et al. (2019). Human iPSC banking: Barriers and opportunities. Journal of Biomedical Science, 26(1). https:\/\/jbiomedsci.biomedcentral.com\/articles\/10.1186\/s12929-019-0578-x","DOI":"10.1186\/s12929-019-0578-x"}],"container-title":["Stem Cell Reviews and Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12015-024-10838-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s12015-024-10838-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s12015-024-10838-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,4]],"date-time":"2025-04-04T14:59:00Z","timestamp":1743778740000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s12015-024-10838-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,17]]},"references-count":68,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,4]]}},"alternative-id":["10838"],"URL":"https:\/\/doi.org\/10.1007\/s12015-024-10838-9","relation":{},"ISSN":["2629-3269","2629-3277"],"issn-type":[{"value":"2629-3269","type":"print"},{"value":"2629-3277","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,17]]},"assertion":[{"value":"23 December 2024","order":1,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 January 2025","order":2,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"No ethics approval was required.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics Approval"}},{"value":"All authors consent to participate.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"All authors consent the publication.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for Publication"}},{"value":"All co-authors have declared no conflicts of interest.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of Interest"}}]}}